Skyrizi 600 mg concentrate for solution for infusion, Guselkumab, Skyrizi 360 mg solution for injection in cartridge clinical trials

A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

This study compares two existing medicines, Guselkumab and Risankizumab (also known as Skyrizi), for adults with Crohn's disease that is moderate to severe. It aims to see which medicine works better and is safer over time to help people feel much better.